Effect evaluation of methylprednisolone plus mitochondrial division inhibitor-1 on spinal cord injury rats
To investigate the combination effect of methylprednisolone (MP) and mitochondrial division inhibitor-1 (Mdivi-1) on the neurological function recovery of rat spinal cord injury (SCI) model.
The weight-drop method was used to establish the rat SCI model; then, rats were randomized into sham group, SCI group, MP group, Mdivi-1 group and MP+Mdivi-1 group. Motor function scores were quantified to evaluate locomotor ability; HE staining was used to assess spinal cord histopathology; tissue water content, oxidative stress, tissue mitochondrial function, neurons apoptosis, and apoptosis-related protein expression were detected.
From the third day after SCI, BBB score of the MP+Mdivi-1 group was obviously higher than the other experimental groups (p < 0.05). Compared with the SCI group, tissue water content of the Mdivi-1 group and MP+Mdivi-1 group reduced obviously (p < 0.05), mitochondrial membrane potential (MMP) level and ATP content in the Mdivi-1 group and MP+Mdivi-1 group were both higher (p < 0.05). Meanwhile, three kinds of treatment all reduced apoptosis significantly, while MP plus Mdivi-1 exhibited the best inhibition effect on apoptosis (p < 0.05). The expression levels of Drp1, cytochrome c, and caspase-3 were all upregulated obviously; Mdivi-1 could inhibit Drp1 upregulation induced by SCI; for the upregulation of cytochrome c and caspase-3, the inhibition effect of Mdivi-1 approached MP. When MP combined with Mdivi-1, there was the best inhibition effect.
MP combined with Mdivi-1 may produce better neurological function recovery, through improving functional status of mitochondria and inhibiting lipid peroxidation in damaged tissue of SCI rats, and thus alleviating apoptosis.
KeywordsMitochondrial division inhibitor-1 Methylprednisolone Neurological function Spinal cord injury
This research was supported by the National Natural Science Fund of China (81371345).
Compliance with ethical standards
Conflict of interest
On behalf of all authors, we state that there is no conflict of interest.
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
- 9.Cassidy-Stone A, Chipuk JE, Ingerman E, Song C, Kuwana T, Kurth MJ, Shaw JT, Hinshaw JE, Green DR, Nunnari J (2008) Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrila outer membrane permeabilization. Dev Cell 14:193–204CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Ruiz A, Alberdi E, Matute C (2018) Mitochondrial division inhibitor 1 (mdivi-1) protects neurons against excitotoxicity through the modulation of mitochondrial function and intracellular Ca2+ signaling. Front Mol Neurosci 11:3. https://doi.org/10.3389/fnmol.2018.00003 CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Suzuki Y, Hasegawa H, Tsuji T, Tsuruda K, Sasaki D, Ishihara K, Nagai K, Yanagihara K, Yamada Y, Kamihira S (2013) Relationships of diverse apoptotic death process patterns to mitochondrial membrane potential (Δψ(m)) evaluated by three-parameter flow cytometric analysis. Cytotechnology 65:59–70CrossRefPubMedGoogle Scholar
- 18.Choi JS, Shin S, Jin YH, Yim H, Koo KT, Chun KH, Oh YT, Lee WH, Lee SK (2007) Cyclin-dependent protein kinase 2 activity is required for mitochondrial translocation of Bax and disruption of mitochondrial transmembrane potential during etoposide-induced apoptosis. Apoptosis 12:1229–1241CrossRefPubMedGoogle Scholar
- 24.Chikuda H, Yasunaga H, Takeshita K, Horiguichi H, Kawaguichi H, Ohe K, Fushimi K, Tanaka S (2014) Mortality and morbidity after high-dose methylprednisolone treatment in patients with acute cervical spinal cord injury: a propensity-matched analysis using a nationwide administrative database. Emerg Med J 31:201–206CrossRefPubMedGoogle Scholar
- 26.Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, Fehlings M, Herr DL, Hitchon PW, Marshall LF, Nockels RP, Pascale V, Perot PL Jr, Piepmeier J, Sonntag VK, Wagner F, Wilberger JE, Winn HR, Young W (1997) Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 277:1597–1604CrossRefPubMedGoogle Scholar